533 related articles for article (PubMed ID: 18095927)
1. Liposomal nanomedicines.
Fenske DB; Cullis PR
Expert Opin Drug Deliv; 2008 Jan; 5(1):25-44. PubMed ID: 18095927
[TBL] [Abstract][Full Text] [Related]
2. Liposomal nanomedicines: an emerging field.
Fenske DB; Chonn A; Cullis PR
Toxicol Pathol; 2008 Jan; 36(1):21-9. PubMed ID: 18337218
[TBL] [Abstract][Full Text] [Related]
3. Entrapment of small molecules and nucleic acid-based drugs in liposomes.
Fenske DB; Cullis PR
Methods Enzymol; 2005; 391():7-40. PubMed ID: 15721372
[TBL] [Abstract][Full Text] [Related]
4. Targeting liposomal nanomedicine to cancer therapy.
Zhong J; Dai LC
Technol Cancer Res Treat; 2012 Oct; 11(5):475-81. PubMed ID: 22475065
[TBL] [Abstract][Full Text] [Related]
5. The liposomal formulation of doxorubicin.
Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines.
Greco F; Vicent MJ
Adv Drug Deliv Rev; 2009 Nov; 61(13):1203-13. PubMed ID: 19699247
[TBL] [Abstract][Full Text] [Related]
7. Anticancer drug delivery with nanoparticles.
Conti M; Tazzari V; Baccini C; Pertici G; Serino LP; De Giorgi U
In Vivo; 2006; 20(6A):697-701. PubMed ID: 17203748
[TBL] [Abstract][Full Text] [Related]
8. Liposomal drug delivery systems: from concept to clinical applications.
Allen TM; Cullis PR
Adv Drug Deliv Rev; 2013 Jan; 65(1):36-48. PubMed ID: 23036225
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticle formulations in pulmonary drug delivery.
Bailey MM; Berkland CJ
Med Res Rev; 2009 Jan; 29(1):196-212. PubMed ID: 18958847
[TBL] [Abstract][Full Text] [Related]
10. Factors affecting toxicity and efficacy of polymeric nanomedicines.
Igarashi E
Toxicol Appl Pharmacol; 2008 May; 229(1):121-34. PubMed ID: 18355886
[TBL] [Abstract][Full Text] [Related]
11. Liposomal nanomedicines as anticancer therapeutics: beyond targeting tumor cells.
Schiffelers RM; Storm G
Int J Pharm; 2008 Dec; 364(2):258-64. PubMed ID: 18773947
[TBL] [Abstract][Full Text] [Related]
12. Use of liposomes as injectable-drug delivery systems.
Ostro MJ; Cullis PR
Am J Hosp Pharm; 1989 Aug; 46(8):1576-87. PubMed ID: 2672806
[TBL] [Abstract][Full Text] [Related]
13. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer.
Malam Y; Loizidou M; Seifalian AM
Trends Pharmacol Sci; 2009 Nov; 30(11):592-9. PubMed ID: 19837467
[TBL] [Abstract][Full Text] [Related]
14. Advances in lipid nanodispersions for parenteral drug delivery and targeting.
Constantinides PP; Chaubal MV; Shorr R
Adv Drug Deliv Rev; 2008 Mar; 60(6):757-67. PubMed ID: 18096269
[TBL] [Abstract][Full Text] [Related]
15. Nanomedicine for cancer: lipid-based nanostructures for drug delivery and monitoring.
Namiki Y; Fuchigami T; Tada N; Kawamura R; Matsunuma S; Kitamoto Y; Nakagawa M
Acc Chem Res; 2011 Oct; 44(10):1080-93. PubMed ID: 21786832
[TBL] [Abstract][Full Text] [Related]
16. Micro- and nanoparticles--medical applications.
Jătariu A; Peptu C; Popa M; Indrei A
Rev Med Chir Soc Med Nat Iasi; 2009; 113(4):1160-9. PubMed ID: 20191893
[TBL] [Abstract][Full Text] [Related]
17. Organic nanocarriers for cancer drug delivery.
López-Dávila V; Seifalian AM; Loizidou M
Curr Opin Pharmacol; 2012 Aug; 12(4):414-9. PubMed ID: 22465543
[TBL] [Abstract][Full Text] [Related]
18. Liposomal drug formulations in cancer therapy: 15 years along the road.
Slingerland M; Guchelaar HJ; Gelderblom H
Drug Discov Today; 2012 Feb; 17(3-4):160-6. PubMed ID: 21983329
[TBL] [Abstract][Full Text] [Related]
19. Tumor priming enhances delivery and efficacy of nanomedicines.
Lu D; Wientjes MG; Lu Z; Au JL
J Pharmacol Exp Ther; 2007 Jul; 322(1):80-8. PubMed ID: 17420296
[TBL] [Abstract][Full Text] [Related]
20. Multifunctional nanocarriers.
Torchilin VP
Adv Drug Deliv Rev; 2006 Dec; 58(14):1532-55. PubMed ID: 17092599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
